Predicting Responses to Neoadjuvant Chemotherapy in Breast Cancer: ACRIN 6691 Trial of Diffuse Optical Spectroscopic Imaging

• Published in: Cancer research (Chicago, Ill.) Vol. 76; no. 20; pp. 5933 - 5944
• Main Authors: Tromberg, Bruce J., Zhang, Zheng, Leproux, Anaïs, O'Sullivan, Thomas D., Cerussi, Albert E., Carpenter, Philip M., Mehta, Rita S., Roblyer, Darren, Yang, Wei, Paulsen, Keith D., Pogue, Brian W., Jiang, Shudong, Kaufman, Peter A., Yodh, Arjun G., Chung, So Hyun, Schnall, Mitchell, Snyder, Bradley S., Hylton, Nola, Boas, David A., Carp, Stefan A., Isakoff, Steven J., Mankoff, David
• Format: Journal Article
• Language: English
• Published: United States 15.10.2016
• Subjects: Adult; Aged; Breast Neoplasms - diagnostic imaging; Breast Neoplasms - drug therapy; Breast Neoplasms - metabolism; Breast Neoplasms - pathology; Chemotherapy, Adjuvant; Female; Hemoglobins - metabolism; Humans; Logistic Models; Middle Aged; Neoadjuvant Therapy; Prospective Studies; ROC Curve; Spectroscopy, Near-Infrared - methods

The prospective multicenter ACRIN 6691 trial was designed to evaluate whether changes from baseline to mid-therapy in a diffuse optical spectroscopic imaging (DOSI)–derived imaging endpoint, the tissue optical index (TOI), predict pathologic complete response (pCR) in women undergoing breast cancer...